← Back

Hefei Lifeon Pharmaceutical Co Ltd

Hefei Lifeon Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical preparations and active pharmaceutical ingredients in China and internationally. The company offers active pharmaceutical ingredients, which includes felodipine, urea, paeonol, doxazosin mesylate, prilocaine, nifedipine, azilsartan kamedoxomil, methylphenidate hydrochloride, dexmethylphenidate HCL, dioctyl sulfosuccinate sodium salt, and DMSA. It also provides intermediate products, such as sodium paeonolsilate, methy2-(2,3-dichlorobenzylidine)-acetoacetate, 3-mercapto-1-propanol, mercaptosuccinic acid and DMPS monohydrate. In addition, it offers nifedipine controlled, doxazosin mesylate, felodipine, trimetazidine dihydrochloride prolonged release tablets; venlafaxine, methylphenidate, and oxycodone hydrochloride prolonged release tablets; chinese medicines; and proxymetacaine hydrochloride, bendazac lysine, timolol maleate, gatifloxacin, jinzhen, pemirolast potassium, and compound dextran eye drops. Further, it provides paeonol ointment, kecuo yintong gel, compound tujingpi gel, metformin and glipizide tablets, and itraconazole and armillarisin oral solution. The company was incorporated in 2002 and is based in Hefei, China.

Price · split & dividend adjusted
News & notes moving 003020.CS
003020.CS▲

Lifang Pharmaceutical's Two Drugs Selected for the 12th National Drug Procurement

Hefei Lifang Pharmaceutical Co., Ltd. announced that its products, doxazosin mesylate extended-release tablets and azilsartan medoxomil potassium tablets, have been selected for the 12th national centralized drug procurement. Doxazosin mesylate extended-release tablets generated sales revenue of 103.4095 million yuan in 2025, accounting for 6.66% of the company's 2025 operating revenue, and 25.3194 million yuan in the first quarter of 2026, accounting for 7.09%. Azilsartan medoxomil potassium tablets were approved for market on May 19, 2026, and have not yet generated sales revenue. The procurement cycle runs from the implementation date of the selection results until December 31, 2029. The company stated that the selection will help increase product market share, but the final agreed procurement volume has not yet been determined.
003020.CS ▲
Jiemian·19dRead more ▾
Biotech & Genomic Medicine▼2

Lifang Pharmaceutical clarifies no brain-computer interface business after three-day winning streak

On the morning of July 13, the innovative drug sector moved higher. Lifang Pharmaceutical hit its third consecutive daily limit up, Harbin Pharmaceutical Group rose for a second straight day, and Xintiandi, Yiling Pharmaceutical, Shuanglu Pharmaceutical, Haofan Bio, and Hisun Pharmaceutical all followed the uptrend. Earlier, Lifang Pharmaceutical announced that it had noticed some self-media outlets labeling it as a brain-computer interface concept stock, but the company has no brain-computer interface-related business or products. Its collaboration with Apon Medical is aimed at jointly exploring synergistic treatment options for attention deficit hyperactivity disorder and will not affect the company's performance. In addition, four of the company's products, including methylphenidate hydrochloride extended-release tablets, have been newly added to the National Essential Medicines List 2026 edition, but product sales remain uncertain. The company's first-quarter 2026 report showed total operating revenue of 357 million yuan, down 0.87 percent year on year, and net profit attributable to shareholders of 35.29 million yuan, down 7.74 percent year on year.
003020.CS ▼
Biotech & Genomic Medicine
市场行情·45dRead more ▾
003020.CS▲

Four Cube Pharma Products Added to National Essential Medicines List

Cube Pharma announced that four of its products have been newly included in the National Essential Medicines List, 2026 edition. With this addition, the company and its subsidiaries now have a total of 15 products on the list. In the first quarter of 2026, Cube Pharma reported revenue of 357 million yuan and net profit attributable to the parent company of 35.29 million yuan.
003020.CS ▲
财中社·49dRead more ▾
© 2026 MarketDXAsset